healthcare

Why This Alzheimer’s Study Is Crushing Biogen Shares

Posted: March 21, 2019 at 9:55 am

Biogen Inc. (NASDAQ: BIIB) shares were crushed in Thursday’s session after the firm announced that it would be discontinuing its late-stage trial for Alzheimer’s disease. Specifically, the firm is discontinuing ...
Read Full Story »

Pfizer Moves Over Half a Billion for Wilson Disease Treatment

Posted: March 20, 2019 at 11:29 am

Pfizer Inc. (NYSE: PFE) has announced that it has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer is looking to ...
Read Full Story »

What’s Next for Altimmune’s Influenza Vaccine

Posted: March 19, 2019 at 9:55 am

Positive results from a midstage influenza study sent Altimmune Inc. (NASDAQ: ALT) shares sharply higher on Tuesday. Specifically, the positive data came from the firm’s Phase 2 extension study of ...
Read Full Story »

What Tilray’s Earnings and Expansion Mean Going Forward

Posted: March 19, 2019 at 9:05 am

When Tilray Inc. (NASDAQ: TLRY) released its most recent quarterly results after the markets closed on Monday, the cannabis firm said that it had a net loss of $0.33 per ...
Read Full Story »

Dermira’s Eczema Treatment Lebrikizumab Breaks Through

Posted: March 18, 2019 at 10:40 am

Dermira Inc. (NASDAQ: DERM) shares more than doubled on Monday after the firm announced midstage results from its eczema study. Specifically, Dermira announced positive results from its Phase 2b dose-ranging ...
Read Full Story »

What Its Antiplatelet Reversal Agent Means for PhaseBio Going Forward

Posted: March 18, 2019 at 9:55 am

PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) shares more than doubled on Monday after the firm released results from an early-stage clinical trial. The results were published online in the New England ...
Read Full Story »

Can Karyopharm’s Myeloma Treatment Selinexor Pass Muster?

Posted: March 15, 2019 at 10:05 am

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares jumped on Friday after the firm announced an update from the U.S. Food and Drug Administration (FDA). Specifically, the FDA has extended the Prescription ...
Read Full Story »

How Much More Talc Fallout Will Johnson & Johnson Face After This $29 Million Verdict?

Posted: March 14, 2019 at 1:45 pm

A California jury has awarded $29 million to a woman who claimed talcum-powder-based Johnson & Johnson (NYSE: JNJ) products caused her cancer. This ruling is the most recent defeat, out of ...
Read Full Story »

Nelson Peltz Very High on Aurora Cannabis

Posted: March 13, 2019 at 9:55 am

News that Aurora Cannabis Inc. (NYSE: ACB) has appointed the notorious activist investor Nelson Peltz as a strategic advisor boosted shares early on Wednesday. Management is hoping to work collaboratively ...
Read Full Story »

Fund Managers Are Wild About 5 Red-Hot Small-Caps Stocks

Posted: March 13, 2019 at 7:00 am

Since the market lows in late 2018, the Russell 2000 Index has been on fire, and the recent pullback in the index may give investors the opportunity to jump in ...
Read Full Story »

Vadadustat Makes the Case for Blockbuster Status After Japanese Chronic Kidney Disease Studies

Posted: March 12, 2019 at 10:45 am

Patients suffering anemia due to chronic kidney disease (CKD) are sure to be content with new positive top-line results from two Phase 3 active-controlled pivotal studies. In this case, they ...
Read Full Story »

Short Sellers Not So High on Marijuana Stocks

Posted: March 12, 2019 at 9:55 am

Cannabis stocks had a huge showing on Wall Street this past fall. In fact, most of the news flow surrounding these stocks had investors pouring money into them. Some of ...
Read Full Story »

Major Biotechs See a Rising Tide in Short Interest

Posted: March 12, 2019 at 9:05 am

The short interest data are out for the most recent settlement date, February 28. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Big Pharma Short Interest Backs Off, With One Huge Exception

Posted: March 12, 2019 at 8:35 am

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Great News for Adolescents with Moderate to Severe Atopic Dermatitis

Posted: March 11, 2019 at 4:14 pm

In an incredible move for adolescent patients 12 to 17 years of age, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for patients with moderate-to-severe atopic dermatitis. ...
Read Full Story »